Clinical-stage oncology company developing first-in-class antibody-based therapies for cancer, using its proprietary OGAP®-Verify proteomic platform for novel target discovery in ADCs, TCEs and other modalities.
Three Phase III trials will test DLL3-targeting obrixtamig in SCLC and epNEC, and HER2 TKI zongertinib as adjuvant therapy in resectable HER2‑mutant NSCLC.
